Cell-Free 59 kDa Immunoreactive Integrin-Linked Kinase

Purpose: We reported that the expression of integrin-linked kinase (ILK) is up-regulated in ovarian carcinomas and that ovarian cancer cells have high expression of ILK. In this study, we have examined the expression of cell-free 59 kDa immunoreactive (ir)ILK in the serum and peritoneal fluid (PTF) of patients with ovarian cancer and evaluated its potential as a serum biomarker for early-stage screening and for monitoring clinical status of patients after chemotherapy treatment. Experimental Design: Thirty-six serum specimens, including normal (n = 6), benign (n = 6), borderline (n = 4), grade 1 (n = 5), grade 2 (n = 5), and grade 3 (n = 10), were evaluated for the expression of irILK by Western blotting. The expression of irILK was evaluated in PTF (n = 10) and peritoneal washings from women with benign ovarian cysts (n = 4). In addition, tissue-conditioned medium obtained from the cultures of primary ovarian tumors (n = 9) was examined for the presence of irILK. Finally, the potential of serum irILK as a biomarker for ovarian cancer screening was evaluated by comparison with cancer antigen 125 (CA 125) concentrations in cancer patients before and after chemotherapy. Results: irILK expression was present in normal serum and in serum of patients with benign ovarian tumors. irILK expression was 6–9-fold higher in the serum of patients with grade 1, grade 2, and grade 3 ovarian cancer than in the serum of healthy volunteers and patients with benign ovarian tumors (P < 0.01). Enhanced expression of irILK in the serum of ovarian cancer patients correlated with the concentration of CA 125. High expression of irILK was present in all 10 PTF tested. Tissue-conditioned medium prepared from malignant ovarian tumors had 4-fold more irILK expression than conditioned medium obtained from borderline and benign tumors (P < 0.01). irILK expression in serum of cancer patients was reduced to basal normal levels after six cycles of Taxol/carboplatin and was consistent with the change of CA 125 levels before and after chemotherapy. Conclusions: These data suggest that irILK is an ovarian tumor-associated antigen and implicates its potential not only as a biomarker for early-stage screening but also as a marker for monitoring the clinical condition of patients after treatment.

[1]  C. Riley,et al.  Integrin‐linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid , 2003, The Journal of pathology.

[2]  Takao Sakai,et al.  Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. , 2003, Genes & development.

[3]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[4]  P. Paley.  Ovarian cancer screening: are we making any progress? , 2001, Current opinion in oncology.

[5]  C. Turner,et al.  Integrin-linked Kinase (ILK) Binding to Paxillin LD1 Motif Regulates ILK Localization to Focal Adhesions* , 2001, The Journal of Biological Chemistry.

[6]  C. G. Zervas,et al.  Drosophila Integrin-Linked Kinase Is Required at Sites of Integrin Adhesion to Link the Cytoskeleton to the Plasma Membrane , 2001, The Journal of cell biology.

[7]  L. Donehower,et al.  The Integrin-linked Kinase Regulates the Cyclin D1 Gene through Glycogen Synthase Kinase 3β and cAMP-responsive Element-binding Protein-dependent Pathways* , 2000, The Journal of Biological Chemistry.

[8]  L. Grabel,et al.  Phosphorylation of the beta1 integrin cytoplasmic domain: toward an understanding of function and mechanism. , 2000, Experimental cell research.

[9]  S. Dedhar.  Cell-substrate interactions and signaling through ILK. , 2000, Current opinion in cell biology.

[10]  S. Dedhar,et al.  Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. , 1999, Trends in cell biology.

[11]  S. Dedhar,et al.  Integrin-linked Protein Kinase Regulates Fibronectin Matrix Assembly, E-cadherin Expression, and Tumorigenicity* , 1998, The Journal of Biological Chemistry.

[12]  S. Dedhar,et al.  Overexpression of the Integrin-linked Kinase Promotes Anchorage-independent Cell Cycle Progression* , 1997, The Journal of Biological Chemistry.

[13]  K. Yamada,et al.  The Regulation of Expression of Integrin Receptors , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[14]  S. Dedhar,et al.  Regulation of cell adhesion and anchorage-dependent growth by a new β1-integrin-linked protein kinase , 1996, Nature.

[15]  J. Brugge,et al.  Integrins and signal transduction pathways: the road taken. , 1995, Science.

[16]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[17]  R. Bast,et al.  CA 125 for the monitoring of ovarian carcinoma during primary therapy , 1987, Obstetrics and gynecology.

[18]  S. Silverberg.  Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[19]  S. Dedhar,et al.  Protein kinase mediators of integrin signal transduction , 1997, Journal of Molecular Medicine.